Total Reports
35
Below-median volume
Breed profile · FDA CVM July 2026 extract
Adverse-event filings for Wolf Hybrid (Other Canids) in the FDA Center for Veterinary Medicine openFDA extract. Browse other canids breeds, reactions, and outcomes below.
By recorded gender -- every report on file for Wolf Hybrid, no filtering.
Data updated September 2026
The verdict
According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Wolf Hybrid ranks #306 of 510 by total reports (35). Death-coded-share rank requires at least 50 reports. National dual: Retriever - Labrador is #1 of 510 by total adverse-event reports (93,675) at death-coded-share rank 195 of 275 breeds with at least 50 reports (3.7%); separately, Atlantic Salmon (Salmo salar) is #1 highest death-coded share at 99.0% (report rank #233).
Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.
Release-over-release change
PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Wolf Hybrid has 35 reports now versus 35 in that prior snapshot: 0 the same number of (0.0%).
This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.
Subscribe to Wolf Hybrid changesTotal Reports
35
Below-median volume
Deaths Reported
1
of 35 reports
Death-coded share of reports
2.9%
2.9% death-coded
Avg Age at Report
5.2 yr
37.3 kg avg weight
2.9% of 35 wolf hybrid reports involved a death outcome.
Read alongside breed popularity, veterinary access, and owner awareness, these shape how many events ever reach the FDA. The comparison line marks the cross-breed median death-coded share (4.8%) among breeds with 50 or more reports; values above it suggest higher reporting bias toward severe outcomes, not necessarily higher true mortality.
| Year | Reports | Trend |
|---|---|---|
| 2011 | 2 | |
| 2012 | 2 | |
| 2013 | 4 | |
| 2014 | 3 | |
| 2015 | 7 | |
| 2017 | 2 | |
| 2018 | 3 | |
| 2019 | 3 | |
| 2020 | 1 | |
| 2024 | 4 | |
| 2025 | 4 | |
Signature read: Wolf Hybrid's 2.9% death-coded share is in the lower third of the ≥50-report cohort (median 4.8%). According to FDA CVM filings indexed on PlainBreed as of July 2026 extract, Wolf Hybrid sits at #307 of 510 by report volume among all breeds and #1 of 1 among other canids breeds, with 35 reports and 1 (2.9%) death-coded. Mean age at report: 5.2 years, average weight 37.3 kg (82.2 lbs).
Top reported signs: Vomiting (10), Lethargy (see also Central nervous system depression in 'Neurological') (4), Lack of efficacy (endoparasite) - heartworm (4). Most-referenced drug: Spinosad (6 reports), followed by Milbemycin Oxime + Spinosad (5) and Ivermectin + Pyrantel As Pamoate Salt (5).
Outcome coding on 35 status-recorded reports is dominated by Recovered/Normal (40.0%). Annual submissions ranged 1-2,025 across 11 years on file.
Two openFDA-derived peer sets for Wolf Hybrid, both outside the Other Canids family so the neighborhoods are not species containment (the similar-volume list above stays within species).
Nearest other-species breeds by reported average weight (37.3 kg here).
What to do with this other canids
A report does not prove a drug caused the reaction, and popular breeds simply generate more reports.
Compare a breed's report volume against how common the breed is before drawing conclusions. See our methodology for how the death-coded share and rankings are computed, or read breed-specific reporting patterns and FDA CVM reporting.
Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025
Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →